Výsledky vyhledávání - "Kensuke Nakazawa"

Akademický článek

Long‐term follow‐up of unresectable adenoid cystic carcinoma of the trachea and bronchus treated with high‐dose proton beam therapy: A report of two cases

Autor: Masatoshi Nakamura, Kayoko Ohnishi, Kensuke Nakazawa, Kei Shimizu, Daigo Miyauchi, Masashi Mizumoto, Kei Nakai, Toshiyuki Okumura, Hideyuki Sakurai

Publikováno v: Thoracic Cancer, Vol 15, Iss 2, Pp 201-205 (2024)

Abstract Adenoid cystic carcinoma (ACC) of the trachea is a rare disease that is slow growing and has a risk of distant metastasis. The standard treatment for ACC of the trachea is surgery, but this tumor is often unresectable. In definitive radiothe

Externí odkaz: https://doaj.org/article/8fd8bb8032c643f3b4c10dfb8097a39c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

Autor: Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD

Publikováno v: JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)

Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma

Externí odkaz: https://doaj.org/article/67a827674fcd4c4087dafceff77375be

Zobrazit plný text záznamu

Akademický článek

Long‐term outcomes of high‐dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall‐cell lung cancer

Autor: Kayoko Ohnishi, Hitoshi Ishikawa, Kensuke Nakazawa, Toshihiro Shiozawa, Yutaro Mori, Masatoshi Nakamura, Toshiyuki Okumura, Ikuo Sekine, Nobuyuki Hizawa, Hideyuki Sakurai

Publikováno v: Thoracic Cancer, Vol 12, Iss 9, Pp 1320-1327 (2021)

Abstract Background To evaluate the long‐term outcomes of high‐dose (74 GyE) proton beam therapy (PBT) with concurrent chemotherapy for stage III non‐small cell lung cancer (NSCLC). Methods Between July 2007 and March 2018, 45 patients with sta

Externí odkaz: https://doaj.org/article/73fb999c530c4c8191b3021306ed1cfa

Zobrazit plný text záznamu

Akademický článek

Small-Cell Lung Cancer Treatment of Newly Diagnosed Patients with Poor Performance Status

Autor: Yuka Aida, Kensuke Nakazawa, Toshihiro Shiozawa, Ryoko Ogawa, Takumi Kiwamoto, Yuko Morishima, Toru Sakamoto, Ikuo Sekine, Nobuyuki Hizawa

Publikováno v: Case Reports in Oncology, Vol 12, Iss 2, Pp 613-620 (2019)

Small-cell lung cancer (SCLC) is highly sensitive to platinum-based chemotherapy. However, its indication in patients with a poor performance status (PS) at initial diagnosis is controversial. We retrospectively reviewed all clinical courses of patho

Externí odkaz: https://doaj.org/article/eb912564c36a40df80d6ca712b0e4b6b

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer

Autor: Toshihiro Shiozawa, Ikuo Sekine, Yuka Aida, Hiroko Watanabe, Kensuke Nakazawa, Koichi Kurishima, Hiroaki Satoh, Nobuyuki Hizawa

Publikováno v: Case Reports in Oncology, Vol 11, Iss 3, Pp 622-632 (2018)

Background: Sensitive-relapsed small-cell lung cancer (SCLC) is thought to be sensitive to chemotherapy; therefore, second-line chemotherapy is recommended. Although platinum rechallenge is performed in the second-line chemotherapy for sensitive-rela

Externí odkaz: https://doaj.org/article/a8ea2d926ab74fdabce18a76116d375a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání